The antivirals are licensed for use in adults with compensated liver disease who are treatment-naive or in whom previous treatment with interferon alfa (pegylated
), alone or in combination with ribavirin
, has failed.
Boceprevir and telaprevir are orally active and suppress viral replication via inhibition of the HCV NS3 protease. They are both used in combination with peginterferon alfa and ribavirin; telaprevir is given for 12 weeks and boceprevir for up to 44 weeks.
NICE guidance on boceprevir
NICE guidance on telaprevir
View Victrelis drug record
View Incivo drug record